GSK (NYSE: GSK) Cuts 2024 Vaccine Sales Forecast Amid Soft Demand for RSV and Shingles Shots
On Wednesday, GSK (NYSE: GSK) said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory […]
NYSE: GSK
GSK Sues Moderna Over mRNA Patent Infringement
GlaxoSmithKline (NYSE: GSK), the British drugmaker, sued Moderna (NASDAQ: MRNA) in U.S. federal court in Delaware on Tuesday, accusing it
GSK Sues Moderna Over mRNA Patent Infringement Read More »
GSK (NYSE: GSK) Stock Surges After $2.2 Billion Zantac Lawsuits Settlement
Shares of GSK (NYSE: GSK) rose about 6% on Wednesday after the British drugmaker struck a $2.2 billion settlement over U.S.
GSK (NYSE: GSK) Stock Surges After $2.2 Billion Zantac Lawsuits Settlement Read More »
Pfizer and GSK RSV Vaccine Sales Fall in US as Millions Fewer People Line Up
U.S. sales of RSV vaccines from GSK (NYSE: GSK) and Pfizer (NYSE: PFE) are down significantly after regulators narrowed the
Pfizer and GSK RSV Vaccine Sales Fall in US as Millions Fewer People Line Up Read More »
Pfizer Secures Legal Victory Against GSK in RSV Vaccine Patent Dispute
LONDON – On Monday, Pfizer (NYSE: PFE) won a bid in a London court to invalidate two of GSK’s (NYSE:
Pfizer Secures Legal Victory Against GSK in RSV Vaccine Patent Dispute Read More »
Sanofi, GSK, CSL Secure $72 Million Funding to Expand US Bird Flu Vaccine Supply
GSK (NYSE: GSK), Sanofi (NASDAQ: SNY), and CSL Ltd have secured $72 million from the U.S. government to ramp up
Sanofi, GSK, CSL Secure $72 Million Funding to Expand US Bird Flu Vaccine Supply Read More »
GSK (NYSE: GSK) Settles Two California Lawsuits Over Heartburn Drug Zantac
On Wednesday, GSK (NYSE: GSK), the British drugmaker, said it had agreed to settle two lawsuits in California that claimed
GSK (NYSE: GSK) Settles Two California Lawsuits Over Heartburn Drug Zantac Read More »
GSK (NYSE: GSK) Advances mRNA Flu Vaccine to Late-Stage Trials
On Thursday, GSK (NYSE: GSK), the British drugmaker, announced positive results from a mid-stage trial of its seasonal influenza vaccine
GSK (NYSE: GSK) Advances mRNA Flu Vaccine to Late-Stage Trials Read More »
GSK (NYSE: GSK) to Seek Dismissal of Florida Zantac Case Over Prostate Cancer Claims
On Friday, British drugmaker GSK (NYSE: GSK) said it would seek a dismissal of an upcoming Zantac case in Florida,
GSK (NYSE: GSK) to Seek Dismissal of Florida Zantac Case Over Prostate Cancer Claims Read More »
